Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The ...

Y-mAbs Therapeutics reported strong ex-U.S. DANYELZA growth amid U.S. headwinds, supported by new market penetration and the recent NCCN guideline inclusion. The company reaffirmed its full-year ...

Y-mAbs Therapeutics YMAB is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

We've discovered 3 warning signs about Y-mAbs Therapeutics. View them for free. A look at the shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) can tell us which group is most powerful.

Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note published on Monday morning,RTT News reports. The brokerage currently ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

Y-mAbs Therapeutics shares last traded at $14.60, with a volume of 78,421 shares trading hands. The company reported ($0.16) earnings […] Skip to main content ...

It did not provide a range for net loss. Before you buy stock in Y-mAbs Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best ...

Cancer drug developer Y-mAbs Therapeutics (NASDAQ: YMAB) didn't exactly kick off the stock trading week on a high note. The company's shares closed the day more than 11% lower in price ...

"One word of truth outweighs the world.”― Aleksandr I. Solzhenitsyn Y-mAbs Therapeutics, Inc. is a New York City based commercial stage biopharmaceutical concern focused on the development of ...

Over the past 3 months, 7 analysts have published their opinion on Y-mAbs Therapeutics (NASDAQ:YMAB) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shares have had a really impressive month, gaining 104% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the ...